Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2022

Ipsen - Disrupting the landscape: the Plus One in RCC and NSCLC

Triple, double and monotherapy: what is the sequence for best outcomes?

Date

11 Sep 2022

Session

Ipsen - Disrupting the landscape: the Plus One in RCC and NSCLC

Topics

Tumour Site

Renal Cell Cancer

Presenters

Sumanta Pal

Authors

J. Bedke1, G.A. De Velasco Oria2, S.K. Pal3

Author affiliations

  • 1 Urology Dept., Crona Kliniken - Universitätsklinikum Tübingen, 72076 - Tübingen/DE
  • 2 Medical Oncology Department, Hospital Universitario 12 de Octubre, 28041 - Madrid/ES
  • 3 City of Hope Comprehensive Cancer Center, 91010 - Duarte/US

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Welcome & agenda

Presenter: Laurence Albiges

Session: Ipsen - Disrupting the landscape: the Plus One in RCC and NSCLC

Resources:

Webcast

Closing

Presenter: Laurence Albiges

Session: Ipsen - Disrupting the landscape: the Plus One in RCC and NSCLC

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.